(PINKSHEETS: APGR), (OTC Bulletin Board: TDON), (OTCBB: MDVX), (OTC Bulletin Board: IMYN).

RealPennies.com: Turning Pennies into dollars: (PINKSHEETS: APGR), (OTC Bulletin Board: TDON), (OTCBB: MDVX), (OTC Bulletin Board: IMYN).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://aprg.realpennies.com

Alpine TLI Group, Inc. (PINKSHEETS: APGR)(January 16, 2008), a full service tax lien and tax deed purchase, research, and property management company, announced yesterday that it has registered to participate in Arizona's Maricopa County tax sale. This sale will begin on Jan. 17th and continue through Feb. 1st. Historically, Maricopa has offered over 20,000 tax liens for sale with a total property value of over $2 Billion. Maricopa offers many opportunities for Alpine to pick up liens on property for as little as 1% of the property value.

M. Taylor Abegg, II, Chief Executive Officer of Alpine TLI Group, Inc., stated, "We are excited to participate in the first big tax sale of the year. Alpine will not only have more than $2 Billion in property to choose from but the tax sale in Maricopa County offers some unique opportunities for experienced investors, such as Alpine. One major benefit will be the reduced acquisition costs associated with this sale. Maricopa County's tax sale is online which allows Alpine to bid on property tax liens without incurring the cost of placing representatives onsite to participate in the sale. We look forward with great anticipation to the results of Maricopa's sale."

ALPINE TLI GROUP, Inc. is a full service tax lien and tax deed purchase, research, and property management company. Alpine specializes in identifying and researching properties that have the propensity of creating a highly leveraged investment opportunity through the purchase of real estate tax lien certificates and tax deeds.

It is estimated that over $10 Billion in property tax liens are offered for sale annually representing over $1 Trillion in potential property value profits for the purchasers of these tax liens. Tax lien certificates are typically acquired by Alpine for 1% to 20% of the property value. If the lien is redeemed by the property owner, a return of 4% to 25% APR is realized by Alpine. If the lien is not redeemed, the deed to the property is granted to Alpine, free and clear of all encumbrances. More information on Alpine TLI Group is available online at http://www.AlpineTLIGroup.com/.

For more info: http://tdon.realpennies.com

Third-Order Nanotechnologies, Inc. (OTC Bulletin Board: TDON), (January 17, 2008), a technology company focused on the development of electro-optic polymer materials for applications in high-speed fiber-optic telecommunications and optical computing, announced that they have retained the Investor Relations Group, Inc. ("IRG"), a thirteen year old, highly-recognized corporate communications firm based in New York City, to serve as its national public relations and investor relations firm.

The Investor Relations Group's award-winning healthcare public relations department will reach out to the media-at-large, namely editors, writers and producers of national, trade and consumer print and broadcast outlets, with the primary focus of educating the public about Third-Order's unique materials and potential products. Simultaneously, IRG's investor relations team will use proprietary competitive analysis strategies and very extensive databases to target the broad scope of the investment community, including portfolio managers and analysts. The program will include pre-qualified one-on-one introductions and general traditional outreach.

"Third-Order sees a future in which Internet bandwidth is essentially free," said Hal Bennett, Chief Executive Officer of Third-Order Nanotechnologies, Inc. "By means of our technology that we expect to allow us to inexpensively fabricate high-speed fiber optic communications chips made out of plastic, we hope to create this future. As we move forward with our vision and begin to grow, the Investor Relations Group will play an integral part in communicating Third-Order's message to the investment community at large."

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of Alternative Public Offering (APO) companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at www.investorrelationsgroup.com.

Third-Order Nanotechnologies is a development stage company, moving toward prototype demonstration and commercialization of its high-activity, high- stability organic polymers for applications in electro-optical device markets. Electro-optical devices convert data from electric signals into optical signals for use in high-speed fiber-optic telecommunications systems and optical computers. Third-Order Nanotechnologies, Inc. is a portfolio company of Universal Capital Management, Inc. (OTC Bulletin Board: UCMT). Please visit the Company's website, www.third-order.com for more information.

For more info: http://mdvx.realpennies.com

Modavox, Inc. (OTCBB: MDVX)(January 16, 2008), Internet broadcasting pioneer and holder of several patented technologies, announced yesterday that it has partnered with Sounds True to deliver a live Internet Pay-Per-View event for bestselling author of the book The Power of Now, Eckhart Tolle.

Eckhart Tolle is widely recognized as one of the most original and inspiring spiritual teachers of our time. His profound yet simple and practical teachings have helped thousands of people find inner peace, healing, and greater fulfillment in their lives. For more information, please visit www.eckharttolle.com.

Sounds True is an independent multimedia publishing company that embraces the world's major spiritual traditions, as well as the arts and humanities, embodied by the leading authors, teachers, and visionary artists of our time. For more information, please visit www.soundstrue.com.

Modavox, Inc., the customized communications company, is a pioneer in Internet broadcasting, producing and syndicating online audio and video, offering innovative, effective, and comprehensive online tools for reaching targeted niche communities worldwide. For more information, please visit www.modavox.com.

For more info: http://imyn.realpennies.com

Immunosyn Corporation (OTC Bulletin Board: IMYN)(January 17, 2008)announced that Proteus Equity Research Partners, a privately-held equity research company, has released an Equity Research Profile on the Company. The report provided an implied value of the Company's Common Stock at $32 per Share.

The Company's revolutionary drug therapy, SF-1019, has shown efficacy treating Multiple Sclerosis (MS) and a wide range of conditions and diseases currently unmet by existing drug and medical therapies. The Company's breakthrough drug, SF-1019, addresses a $90 billion worldwide market.

Proteus Equity Research Partners is a multi-faceted investment research firm focusing on the provision of comprehensive independent equity research, analysis, and financial modeling. Proteus offers strategic business plan development, market research, and specialized private transactional research. Proteus' reputation for excellence, breadth of research, and client interaction reflects the abilities and accomplishments of our team. Additional information is available at www.ProteusEquityResearch.com.

The authors contributing to this report do not hold any shares of Immunosyn Corporation (IMYN). Additionally, the authors' contributing to this report certify that the views expressed herein accurately reflect the authors' views as to the subject securities and issuers. Proteus certifies that no part of the authors' compensation was, is, or will be, directly or indirectly, related to the views expressed in the report. Proteus has been compensated a total of $3,000 from Securities Magazine, Inc. for preparation and production of this report. This report is based on data obtained from sources believed to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. The report should not be construed as investment advice. Any opinions expressed herein are subject to change.

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com